GlassScriptPhysician profile
Marlisha Edwards
NPI 1225321748
$4,549.49
in general payments reported to CMS, 2019-2025
26 companies · $730 in 2025
The $730 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $145 · 2021: $328 · 2022: $585 · 2023: $1,139 · 2024: $1,240 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $763.31 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $676.31 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $639.70 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Lilly USA, LLC | $460.36 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novartis Pharmaceuticals Corporation | $301.80 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.63 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $257.09 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $196.73 | 2024 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $169.68 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $131.19 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $127.25 | 2022-2025 | |
| Boston Scientific Corporation | $121.88 | 2019 | |
| Astellas Pharma US INC | $95.95 | 2023-2024 | Veozah |
| Amneal Pharmaceuticals LLC | $57.08 | 2024-2025 | Unithroid |
| Viatris Specialty LLC | $44.79 | 2025 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $31.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.56 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $26.79 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $26.37 | 2019 | |
| Lundbeck LLC | $23.70 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.58 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $20.14 | 2025 | Heplisav-B |
| Exact Sciences Corporation | $17.12 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $16.06 | 2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $15.69 | 2024 | Zoryve |
| Glaxosmithkline, LLC. | $13.80 | 2023 | Bexsero, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlisha Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.